WEBULL
News
REVBW
0.0102
-2.86%
-0.0003
Weekly Report: what happened at REVBW last week (1208-1212)?
Weekly Report · 3d ago
Weekly Report: what happened at REVBW last week (1201-1205)?
Weekly Report · 12/08 10:06
Revelation Biosciences Prepares Gemini for Late-Stage Acute Kidney Injury Trials
Reuters · 12/03 22:02
Weekly Report: what happened at REVBW last week (1124-1128)?
Weekly Report · 12/01 10:03
Weekly Report: what happened at REVBW last week (1117-1121)?
Weekly Report · 11/24 10:07
Revelation Biosciences Advances Gemini Toward FDA Review for Acute Kidney Injury
Reuters · 11/20 14:00
Weekly Report: what happened at REVBW last week (1110-1114)?
Weekly Report · 11/17 10:07
Weekly Report: what happened at REVBW last week (1103-1107)?
Weekly Report · 11/10 10:05
Revelation Biosciences Q3 net loss narrows to $1.9 mln
Reuters · 11/06 22:10
Revelation Biosciences reports $1.9 million net loss for Q3 2025
Reuters · 11/06 21:27
Weekly Report: what happened at REVBW last week (1027-1031)?
Weekly Report · 11/03 10:05
Weekly Report: what happened at REVBW last week (1020-1024)?
Weekly Report · 10/27 10:07
Weekly Report: what happened at REVBW last week (1013-1017)?
Weekly Report · 10/20 10:05
Weekly Report: what happened at REVBW last week (1006-1010)?
Weekly Report · 10/13 10:07
Weekly Report: what happened at REVBW last week (0929-1003)?
Weekly Report · 10/06 10:04
Weekly Report: what happened at REVBW last week (0922-0926)?
Weekly Report · 09/29 10:05
Revelation Biosciences Inc. Announces Date for Special Stockholders Meeting
Reuters · 09/23 16:16
Weekly Report: what happened at REVBW last week (0915-0919)?
Weekly Report · 09/22 10:05
Weekly Report: what happened at REVBW last week (0908-0912)?
Weekly Report · 09/15 11:15
Revelation Biosciences Inc. Announces Date for Special Stockholders Meeting
Reuters · 09/12 20:08
More
Webull provides a variety of real-time REVBW stock news. You can receive the latest news about Rvltn Bioscnc through multiple platforms. This information may help you make smarter investment decisions.
About REVBW
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).